Melanoma Clinical Trials in Ohio

Showing 281-300 of 325 trials

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

NCT01462773

The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.

Melanoma

Ohio State University Comprehensive Cancer Center16 participantsStarted Jan 2006

Columbus, Ohio, United States

COMPLETEDPhase 332 miles

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007

The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).

Melanoma

Bayer270 participantsStarted May 2005

Birmingham, Alabama, United States • Tucson, Arizona, United States • Los Angeles, California, United States +63 more locations

PreviousPage 15 of 17Next

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma Trials in Other Cities

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Ohio